Related Experiment Video
Updated: Aug 13, 2026

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
Published on: February 12, 2017
Paclitaxel plus nonanthracycline combinations in metastatic breast cancer
1Division of Hematology/Oncology, Mayo Foundation and Mayo Clinic, Jacksonville, FL 32224, USA.
Abstract:
The results of several phase II and some phase III studies are now available in which the combination of paclitaxel (Taxol; Bristol-Myers Squibb Company, Princeton, NJ) and nonanthracycline agents are evaluated. The studies demonstrate the activity and feasibility of these combinations, which achieved response rates of 40% to 80% and median time to progression that exceeded 6 months. The potential role of these combinations compared with older non-paclitaxel-containing regimens, in improving quality of life, response rate, and survival in patients with metastatic breast cancer, however, await the results of prospective, randomized phase III trials. The next logical step, depending on the results of planned comparative trials, is to incorporate these combinations in the neoadjuvant and adjuvant settings.
More Related Videos
06:02Live Imaging to Study Microtubule Dynamic Instability in Taxane-resistant Breast Cancers
Published on: February 20, 2017
08:57Sample Extraction and Simultaneous Chromatographic Quantitation of Doxorubicin and Mitomycin C Following Drug Combination Delivery in Nanoparticles to Tumor-bearing Mice
Published on: October 5, 2017
Related Concept Videos
Drugs that Stabilize Microtubules
Targeted Cancer Therapies
There are several types of targeted therapies against specific...
Treatment Resistant Cancers
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Targeted Cancer Therapies
There are several types of targeted therapies against specific...
Treatment Resistent Cancers